Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

Delavirdine mesylate (DLV) is a potent nonnucleoside reverse transcriptase inhibitor with activity specific for human immunodeficiency virus type 1. In the present phase I/II study we evaluated the safety, toxicity, pharmacokinetics, and antiretroviral activities of two-drug and three-drug combinati...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Davey, R T, Chaitt, D G, Reed, G F, Freimuth, W W, Herpin, B R, Metcalf, J A, Eastman, P S, Falloon, J, Kovacs, J A, Polis, M A, Walker, R E, Masur, H, Boyle, J, Coleman, S, Cox, S R, Wathen, L, Daenzer, C L, Lane, H C
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1996
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163391/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8807058/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.40.7.1657
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!